Ustekinumab: “Real-world” outcomes and potential predictors of nonresponse in treatment-refractory Crohn’s disease

BACKGROUND: Ustekinumab was approved in Europe for the treatment of adults with moderate to severe Crohn's disease (CD) in 2016, and there is an urgent need for data on its everyday use. AIM: To obtain data on the daily use of ustekinumab. METHODS: This is a retrospective monocentric study. Pat...

Full description

Saved in:
Bibliographic Details
Published in:World J Gastroenterol
Main Authors: Hoffmann, Peter, Krisam, Johannes, Wehling, Cyrill, Kloeters-Plachky, Petra, Leopold, Yvonne, Belling, Nina, Gauss, Annika
Format: Artigo
Language:Inglês
Published: Baishideng Publishing Group Inc 2019
Subjects:
Retrospective Study
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6710179/
https://ncbi.nlm.nih.gov/pubmed/31496626
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v25.i31.4481
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items